Noxopharm CEO Dr Gisela Mautner added, “We are very grateful to the Tour de Cure team for funding this promising research. With this grant, our preclinical drug candidate is recognised as having potential that warrants further investigation and development." …
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate
April 22, 2024 Australian Biotech
Latest Video
New Stories
-
Pilot study confirms adjunct NB-UVB needed to activate repigmentation in vitiligo
June 18, 2025 - - Australian Biotech -
Montu pushes for national standards at Productivity Commission inquiry
June 17, 2025 - - Latest News -
Canadian appointed to lead New Zealand's Pharmac
June 17, 2025 - - Latest News -
US FDA approves CSL's treatment for hereditary angioedema
June 17, 2025 - - Latest News -
Australia's system is more uniform than the US, but not uniformly better
June 17, 2025 - - Latest News -
Australian company secures FDA approval to progress development of CAR-T therapy
June 16, 2025 - - Latest News -
These systems are and always have been more similar than most realise
June 16, 2025 - - Latest News